Should I buy or sell Bio-Techne stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TECH shares. View TECH analyst ratings or view top-rated stocks .

What is Bio-Techne's stock price target for 2024?

9 equities research analysts have issued 12-month price targets for Bio-Techne's stock. Their TECH share price targets range from $65.00 to $120.00. On average, they expect the company's share price to reach $84.11 in the next year. This suggests a possible upside of 28.4% from the stock's current price. View analysts price targets for TECH or view top-rated stocks among Wall Street analysts .

How have TECH shares performed in 2024?

Bio-Techne's stock was trading at $77.16 at the start of the year. Since then, TECH shares have decreased by 15.1% and is now trading at $65.52. View the best growth stocks for 2024 here .

When is Bio-Techne's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our TECH earnings forecast .

How can I listen to Bio-Techne's earnings call?

Bio-Techne will be holding an earnings conference call on Wednesday, May 1st at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13745802".

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) released its quarterly earnings data on Thursday, February, 1st. The biotechnology company reported $0.33 earnings per share for the quarter, missing the consensus estimate of $0.36 by $0.03. The biotechnology company had revenue of $272.60 million for the quarter, compared to the consensus estimate of $277.48 million. Bio-Techne had a trailing twelve-month return on equity of 14.21% and a net margin of 19.58%.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne declared a quarterly dividend on Thursday, February 1st. Shareholders of record on Monday, February 12th will be paid a dividend of $0.08 per share on Monday, February 26th. This represents a $0.32 annualized dividend and a yield of 0.49%. The ex-dividend date is Friday, February 9th. Read our dividend analysis for TECH .

Is Bio-Techne a good dividend stock?

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.48%. The dividend payout ratio is 23.19%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 17.58% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for TECH .

What ETFs hold Bio-Techne's stock?

ETFs with the largest weight of Bio-Techne (NASDAQ:TECH) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) , Global X Genomics & Biotechnology ETF (GNOM) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , American Century Mid Cap Growth Impact (MID) , VanEck Biotech ETF (BBH) , BlackRock Future Innovators ETF (BFTR) , Thrivent Small-Mid Cap ESG ETF (TSME) and Fidelity Disruptive Medicine ETF (FMED) .

When did Bio-Techne's stock split?

Bio-Techne shares split on Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were distributed to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com . Charles Kummeth has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX) , Gilead Sciences (gild) , NVIDIA (NVDA) , AbbVie (ABBV) , Amgen (AMGN) , Abbott Laboratories (ABT) , Cisco Systems (CSCO) , Johnson & Johnson (JNJ) , AT&T (T) and Boeing (BA) .

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by many different retail and institutional investors. Top institutional shareholders include Rowlandmiller & PARTNERS.ADV (0.03%), Wealth Enhancement Advisory Services LLC (0.02%), Affiance Financial LLC (0.01%), Fulton Bank N.A. (0.00%), Modus Advisors LLC (0.00%) and CWM LLC (0.00%). Insiders that own company stock include Brenda S Furlow, Brenda S Furlow , Charles R Kummeth, Charles R Kummeth , Glenn Hedde, James Hippel , John L Higgins , Kim Kelderman , Norman David Eansor , Robert V Baumgartner and Roeland Nusse . View institutional ownership trends .

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Bio-Techne have any subsidiaries?

The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences. Read More

NASDAQ:TECH

Bio-Techne (TECH) Stock Price, News & Analysis

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Free TECH Stock Alerts

$65.52

-1.21 (-1.81%)

(As of 04/15/2024 ET)

Compare

Today's Range: $65.10
▼
$67.46
50-Day Range: $65.52
▼
$77.09
52-Week Range: $51.79
▼
$89.91

Volume: 735,416 shs
Average Volume: 940,133 shs
Market Capitalization: $10.30 billion

P/E Ratio: 47.48
Dividend Yield: 0.49%
Price Target: $84.11

Get Bio-Techne alerts:

Bio-Techne MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.78 Rating Score
Upside/Downside: 28.4% Upside
$84.11 Price Target
Short Interest: Bearish
3.38% of Shares Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: -1.76
Upright™ Environmental Score
News Sentiment: 0.91
Based on 6 Articles This Week
Insider Trading: Selling Shares
$800,592 Sold Last Quarter
Proj. Earnings Growth: 18.95%
From $1.53 to $1.82 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.83 out of 5 stars

Medical Sector

36th out of 928 stocks

Biological Products, Except Diagnostic Industry

6th out of 155 stocks

3.4

Analyst's Opinion

Consensus Rating
Bio-Techne has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Bio-Techne has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.38% of the outstanding shares of Bio-Techne have been sold short.
Short Interest Ratio / Days to Cover
Bio-Techne has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Bio-Techne has recently increased by 4.31%, indicating that investor sentiment is decreasing.

1.7

Dividend Strength

Dividend Yield
Bio-Techne has a dividend yield of 0.48%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Bio-Techne does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Bio-Techne is 23.19%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 17.58% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Bio-Techne has received a 61.45% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antibodies", "Biochemical assay kits", and "Biochips" products. See details.
Environmental Sustainability
The Environmental Impact score for Bio-Techne is -1.76.

2.2

News and Social Media Coverage

News Sentiment
Bio-Techne has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Bio-Techne this week, compared to 6 articles on an average week.
Search Interest
Only 8 people have searched for TECH on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bio-Techne insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $800,592.00 in company stock.
Percentage Held by Insiders
Only 4.10% of the stock of Bio-Techne is held by insiders.
Percentage Held by Institutions
98.95% of the stock of Bio-Techne is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Bio-Techne are expected to grow by 18.95% in the coming year, from $1.53 to $1.82 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bio-Techne is 47.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.33.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bio-Techne is 47.48, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 176.61.
Price to Earnings Growth Ratio
Bio-Techne has a PEG Ratio of 7.55. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Bio-Techne has a P/B Ratio of 5.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Bio-Techne Stock (NASDAQ:TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

TECH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TECH Stock News Headlines

April 12, 2024 | theglobeandmail.com

Cell Culture Market worth $57.9 billion by 2029 | MarketsandMarkets™

April 10, 2024 | prnewswire.com

BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS

April 16, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 8, 2024 | prnewswire.com

BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY

April 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Bio-Techne Amid Market Recovery and Strategic Positioning

April 4, 2024 | seekingalpha.com

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

April 3, 2024 | msn.com

RedShiftBio Welcomes Sebastian Arevalo as New Sales Leader

April 3, 2024 | finance.yahoo.com

BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE

April 16, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 1, 2024 | finance.yahoo.com

Bio-Techne (NASDAQ:TECH) shareholders have earned a 7.4% CAGR over the last five years

April 1, 2024 | finance.yahoo.com

BIO-TECHNE RECEIVES CiteAb'S ELISA KIT SUPPLIER OF THE YEAR AND SPATIAL BIOLOGY INNOVATION AWARDS

March 28, 2024 | prnewswire.com

BIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE SPATIAL BIOLOGY SERVICES

March 27, 2024 | finance.yahoo.com

Global Exosome Market Size, Forecast, Trials and Trends Insights - Surging Number of Scientific Papers Investigating Exosomes and their Applications

March 25, 2024 | msn.com

Asuragen’s QuantideX diagnostic test secures IVDR certification

March 22, 2024 | finanznachrichten.de

Bio-Techne Corporation: Bio-Techne Receives European Ivdr Certification For Diagnostic Test To Monitor Chronic Myeloid Leukemia

March 20, 2024 | seekingalpha.com

TECH Bio-Techne Corporation

March 19, 2024 | finanznachrichten.de

Cell Expansion Market Worth $26.7 billion | MarketsandMarkets

March 18, 2024 | investorplace.com

7 Biotech Stocks Ready to Ride the Sector's Resurgence

March 16, 2024 | finance.yahoo.com

TECH Apr 2024 65.000 call

March 16, 2024 | finance.yahoo.com

TECH Apr 2024 60.000 put

March 15, 2024 | seekingalpha.com

Wall Street Lunch: Tick Tock On TikTok

March 12, 2024 | prnewswire.com

BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM

March 11, 2024 | finance.yahoo.com

Director Roeland Nusse Sells 10,400 Shares of Bio-Techne Corp (TECH)

March 6, 2024 | prnewswire.com

BIO-TECHNE TO PRESENT AT THE BARCLAYS 26th ANNUAL GLOBAL HEALTHCARE CONFERENCE

March 2, 2024 | finance.yahoo.com

What Does Bio-Techne Corporation's (NASDAQ:TECH) Share Price Indicate?

February 26, 2024 | benzinga.com

Bio-Techne: Bolstering Investor Value with Reduced Dividends and Amplified Earnings

February 23, 2024 | finance.yahoo.com

What Makes Bio-Techne Corporation (TECH) an Investment Bet?

See More Headlines

Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/01/2024
Ex-Dividend for 2/26 Dividend: 2/09/2024
Dividend Payable: 2/26/2024
Today: 4/16/2024
Next Earnings (Confirmed): 5/01/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Life Sciences Tools & Services
Current Symbol: NASDAQ:TECH
CUSIP: 87837710
CIK: 842023
Web: www.bio-techne.com
Phone: (612) 379-8854
Fax: 612-656-4400
Employees: 3,050
Year Founded: 1981

Price Target and Rating

Average Stock Price Target: $84.11
High Stock Price Target: $120.00
Low Stock Price Target: $65.00
Potential Upside/Downside: +28.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.78
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.38
Trailing P/E Ratio: 47.48
Forward P/E Ratio: 42.82
P/E Growth: 7.55
Net Income: $285.26 million
Net Margins: 19.58%
Pretax Margin: 21.96%
Return on Equity: 14.21%
Return on Assets: 10.36%

Debt

Debt-to-Equity Ratio: 0.23
Current Ratio: 4.37
Quick Ratio: 3.03

Sales & Book Value

Annual Sales: $1.14 billion
Price / Sales: 9.06
Cash Flow: $2.47 per share
Price / Cash Flow: 26.52
Book Value: $12.49 per share
Price / Book: 5.25

Miscellaneous

Outstanding Shares: 157,190,000
Free Float: 150,747,000
Market Cap: $10.30 billion
Optionable: Optionable
Beta: 1.22

Social Links

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Kim Kelderman (Age 56)
CEO, President & Director
Comp: $845.71k
Mr. James T. Hippel (Age 53)
Executive VP of Finance & CFO
Comp: $691.78k
Mr. Shane Bohnen (Age 49)
Senior VP, General Counsel & Corporate Secretary
Comp: $353.6k
Mr. Charles R. Kummeth (Age 64)
Senior Advisor
Comp: $1.26M
Mr. William A. Geist (Age 54)
President of Protein Sciences Segment
Comp: $533.67k
Dr. Gary J. Latham Ph.D.
VP & CTO
David Clair
Senior Director of Investor Relations & Corporate Development
Mr. Gerry Andros
Vice President of Sales and Marketing
Mr. Robert M. Gavin (Age 56)
Vice President of Corporate Development
Comp: $724.51k
Ms. Brenda S. Everson
Senior VP & Chief Human Resources Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TECH Stock Analysis - Frequently Asked Questions

Should I buy or sell Bio-Techne stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TECH shares.
View TECH analyst ratings or view top-rated stocks.
What is Bio-Techne's stock price target for 2024?: 9 equities research analysts have issued 12-month price targets for Bio-Techne's stock. Their TECH share price targets range from $65.00 to $120.00. On average, they expect the company's share price to reach $84.11 in the next year. This suggests a possible upside of 28.4% from the stock's current price.
View analysts price targets for TECH or view top-rated stocks among Wall Street analysts.
How have TECH shares performed in 2024?: Bio-Techne's stock was trading at $77.16 at the start of the year. Since then, TECH shares have decreased by 15.1% and is now trading at $65.52.
View the best growth stocks for 2024 here.
When is Bio-Techne's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our TECH earnings forecast.
How can I listen to Bio-Techne's earnings call?: Bio-Techne will be holding an earnings conference call on Wednesday, May 1st at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13745802".
How were Bio-Techne's earnings last quarter?: Bio-Techne Co. (NASDAQ:TECH) released its quarterly earnings data on Thursday, February, 1st. The biotechnology company reported $0.33 earnings per share for the quarter, missing the consensus estimate of $0.36 by $0.03. The biotechnology company had revenue of $272.60 million for the quarter, compared to the consensus estimate of $277.48 million. Bio-Techne had a trailing twelve-month return on equity of 14.21% and a net margin of 19.58%.
How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?: Bio-Techne declared a quarterly dividend on Thursday, February 1st. Shareholders of record on Monday, February 12th will be paid a dividend of $0.08 per share on Monday, February 26th. This represents a $0.32 annualized dividend and a yield of 0.49%. The ex-dividend date is Friday, February 9th.
Read our dividend analysis for TECH.
Is Bio-Techne a good dividend stock?: Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.48%. The dividend payout ratio is 23.19%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 17.58% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

What ETFs hold Bio-Techne's stock?: ETFs with the largest weight of Bio-Techne (NASDAQ:TECH) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), American Century Mid Cap Growth Impact (MID), VanEck Biotech ETF (BBH), BlackRock Future Innovators ETF (BFTR), Thrivent Small-Mid Cap ESG ETF (TSME) and Fidelity Disruptive Medicine ETF (FMED).
When did Bio-Techne's stock split?: Bio-Techne shares split on Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were distributed to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.
What is Charles Kummeth's approval rating as Bio-Techne's CEO?: 95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.
What other stocks do shareholders of Bio-Techne own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).
Who are Bio-Techne's major shareholders?: Bio-Techne's stock is owned by many different retail and institutional investors. Top institutional shareholders include Rowlandmiller & PARTNERS.ADV (0.03%), Wealth Enhancement Advisory Services LLC (0.02%), Affiance Financial LLC (0.01%), Fulton Bank N.A. (0.00%), Modus Advisors LLC (0.00%) and CWM LLC (0.00%). Insiders that own company stock include Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends.
How do I buy shares of Bio-Techne?: Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Bio-Techne have any subsidiaries?: The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
Read More

This page (NASDAQ:TECH) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial